Interaksi Rizatriptan

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or of an ergotamine-containing medication ( 4 ) (label Rizatriptan, Kontraindikasi)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (label Amfetamin, Peringatan dan perhatian)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (label Amfetamin dan dekstroamfetamin, Peringatan dan perhatian)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Beladona dan opium, Interaksi obat)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3) ] . (label Rizatriptan, Kontraindikasi)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Buprenorfin, Interaksi obat)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Buprenorfin dan nalokson, Interaksi obat)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs SSRIs, and other serotonergic drugs, including buspirone, alone but particularly with concomitant use of other serotonergic drugs (including triptans), with drugs that impair metabolism of serotonin (in particular, MAOIs, including reversible MAOIs… (label Buspiron, Peringatan)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Butalbital, aspirin, kafein, dan kodein, Interaksi obat)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Butalbital, parasetamol, kafein, dan kodein, Interaksi obat)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Butorfanol, Perhatian)

Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans,… (label Dekstroamfetamin, Peringatan)

Concomitant use of Monoamine Oxidase Inhibitors (MAOIs) and serotonergic drugs may potentially cause life threatening adverse events ( see CONTRAINDICATIONS , WARNINGS , and DOSAGE AND ADMINISTRATION ). (label Desipramin, Interaksi obat)

• Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (label Desvenlafaksin, Peringatan dan perhatian)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3) ] . (label Rizatriptan, Kontraindikasi)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Duloksetin, Peringatan dan perhatian)

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or of an ergotamine-containing medication ( 4 ) (label Rizatriptan, Kontraindikasi)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3) ] . (label Rizatriptan, Kontraindikasi)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (label Rizatriptan, Peringatan dan perhatian)

Monoamine Oxidase Inhibitors MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. (label Rizatriptan, Interaksi obat)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (label Fentanil, Peringatan dan perhatian)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (label Rizatriptan, Peringatan dan perhatian)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (label Rizatriptan, Peringatan dan perhatian)

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or of an ergotamine-containing medication ( 4 ) (label Rizatriptan, Kontraindikasi)

Serotonin syndrome has been reported with granisetron products, alone but particularly with concomitant use of serotonergic drugs. (label Granisetron, Peringatan dan perhatian)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Hidrokodon, Interaksi obat)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Hidrokodon dan homatropin, Interaksi obat)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Hidrokodon dan ibuprofen, Perhatian)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (label Hidrokodon dan klorfeniramin, Interaksi obat)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Hidrokodon dan parasetamol, Perhatian)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Hidromorfon, Interaksi obat)

Monoamine Oxidase Inhibitors MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. (label Rizatriptan, Interaksi obat)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3) ] . (label Rizatriptan, Kontraindikasi)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Kodein, Interaksi obat)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (label Levomilnasipran, Peringatan dan perhatian)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Levorfanol, Perhatian)

Monoamine Oxidase Inhibitors MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. (label Rizatriptan, Interaksi obat)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (label Lisdeksamfetamin, Peringatan dan perhatian)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (label Litium, Peringatan dan perhatian)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (label Metadon, Peringatan dan perhatian)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (label Metaksalon, Interaksi obat)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (label Metamfetamin, Peringatan dan perhatian)

Monoamine Oxidase Inhibitors MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. (label Rizatriptan, Interaksi obat)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3) ] . (label Rizatriptan, Kontraindikasi)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (label Milnasipran, Peringatan dan perhatian)

Serotonin Syndrome : Increased risk when co-administered with other serotonergic drugs (e.g., SSRI, SNRI, triptans), but also when taken alone. (label Mirtazapin, Peringatan dan perhatian)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Morfin, Interaksi obat)

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or of an ergotamine-containing medication ( 4 ) (label Rizatriptan, Kontraindikasi)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (label Oksikodon, Interaksi obat)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Oksimorfon, Interaksi obat)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (label Rizatriptan, Peringatan dan perhatian)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Oliseridin, Interaksi obat)

S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (label Ondansetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Parasetamol dan kodein, Perhatian)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (label Rizatriptan, Peringatan dan perhatian)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Pentazosin dan nalokson, Perhatian)

‎ • Serotonin Syndrome with Concomitant Use of Serotonergic Drugs : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (label Petidin, Peringatan dan perhatian)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Prometazin dan kodein, Interaksi obat)

Monoamine Oxidase Inhibitors MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. (label Rizatriptan, Interaksi obat)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (label Remifentanil, Peringatan dan perhatian)

Monoamine Oxidase Inhibitors MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. (label Rizatriptan, Interaksi obat)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (label Rizatriptan, Peringatan dan perhatian)

Immediately discontinue concomitant treatment with TONMYA and a serotonergic agent if serotonin syndrome symptoms occur and initiate supportive symptomatic treatment. (label Siklobenzaprin, Peringatan dan perhatian)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (label Rizatriptan, Peringatan dan perhatian)

Mengombinasikan St. John's wort dengan antidepresan dan obat serotonergik lain meningkatkan risiko sindrom serotonin. (NCCIH, St. John's Wort)

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or of an ergotamine-containing medication ( 4 ) (label Rizatriptan, Kontraindikasi)

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or of an ergotamine-containing medication ( 4 ) (label Rizatriptan, Kontraindikasi)

Serotonin Syndrome with Concomitant Use of Serotonergic Drugs : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (label Tapentadol, Peringatan dan perhatian)

Monoamine Oxidase Inhibitors MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. (label Rizatriptan, Interaksi obat)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (label Trazodon, Peringatan dan perhatian)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (label Rizatriptan, Peringatan dan perhatian)

• Serotonin Syndrome : Increased risk when coadministered with other serotonergic agents, but also when taken alone. (label Vortioksetin, Peringatan dan perhatian)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (label Ziprasidon, Peringatan dan perhatian)

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or of an ergotamine-containing medication ( 4 ) (label Rizatriptan, Kontraindikasi)

The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (label Rizatriptan, Peringatan dan perhatian)

The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (label Rizatriptan, Peringatan dan perhatian)

SSRIs/SNRIs and Serotonin Syndrome Cases of serotonin syndrome have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [see Warnings and Precautions (5.7) ] . (label Rizatriptan, Interaksi obat)

The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (label Rizatriptan, Peringatan dan perhatian)

Drugs that Increase Blood Pressure Administering NORTHERA in combination with other agents that increase blood pressure (e.g., norepinephrine, ephedrine, midodrine, and triptans) would be expected to increase the risk for supine hypertension. (label Droksidopa, Interaksi obat)

The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (label Rizatriptan, Peringatan dan perhatian)

The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (label Rizatriptan, Peringatan dan perhatian)

Nadolol/Metoprolol : In a drug interactions study, effects of multiple doses of nadolol 80 mg or metoprolol 100 mg every 12 hours on the pharmacokinetics of a single dose of 10 mg rizatriptan were evaluated in healthy subjects (n=12). (label Rizatriptan, Interaksi obat)

Nadolol/Metoprolol : In a drug interactions study, effects of multiple doses of nadolol 80 mg or metoprolol 100 mg every 12 hours on the pharmacokinetics of a single dose of 10 mg rizatriptan were evaluated in healthy subjects (n=12). (label Rizatriptan, Interaksi obat)

Nadolol/Metoprolol : In a drug interactions study, effects of multiple doses of nadolol 80 mg or metoprolol 100 mg every 12 hours on the pharmacokinetics of a single dose of 10 mg rizatriptan were evaluated in healthy subjects (n=12). (label Rizatriptan, Interaksi obat)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (label Nalbufin, Interaksi obat)

The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (label Rizatriptan, Peringatan dan perhatian)

Propranolol The dose of MAXALT should be adjusted in propranolol-treated patients, as propranolol has been shown to increase the plasma AUC of rizatriptan by 70% [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3) ] . (label Rizatriptan, Interaksi obat)

The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (label Rizatriptan, Peringatan dan perhatian)

The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (label Rizatriptan, Peringatan dan perhatian)

Triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) should have a cardiovascular evaluation prior to receiving MAXALT. (label Rizatriptan, Peringatan dan perhatian)

Serotonin Syndrome Risk: Potentially life-threatening condition could result from use of Tramadol Hydrochloride Extended-Release Capsules, particularly during concomitant use of serotonergic drugs. (label Tramadol, Peringatan dan perhatian)

Serotonin Syndrome Risk Cases of serotonin syndrome, a potentially life-threatening condition, have been reported with the use of tramadol, including tramadol hydrochloride and acetaminophen, during concomitant use with serotonergic drugs. (label Tramadol dan parasetamol, Peringatan dan perhatian)

The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (label Rizatriptan, Peringatan dan perhatian)

SSRIs/SNRIs and Serotonin Syndrome Cases of serotonin syndrome have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [see Warnings and Precautions (5.7) ] . (label Rizatriptan, Interaksi obat)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (label Rizatriptan, Peringatan dan perhatian)

Medication Overuse Headache Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, or a combination of drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache). (label Rizatriptan, Peringatan dan perhatian)

The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (label Fentermin, Peringatan dan perhatian)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (label Rizatriptan, Peringatan dan perhatian)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (label Rizatriptan, Peringatan dan perhatian)

Medication Overuse Headache Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, or a combination of drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache). (label Rizatriptan, Peringatan dan perhatian)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (label Rizatriptan, Interaksi obat)